HomeMy WebLinkAboutK5885-03-Kittitas County Sheriff - FULLY EXECUTEDDocuSlgn Envelope ID: 6666FU9F-322B-4BB0-BCBO-40579A7ED52C
HCA Contract No.: K5885
Washington State r
CONTRACT
Amendment No.: 3
Health Care Authority
AMENDMENT
for MOUD in Jails
THIS AMENDMENT TO THE CONTRACT is between the Washington State Health Care Authority and the party
whose name appears below and is effective as of the date set forth below.
CONTRACTOR NAME
CONTRACTOR doing business as (DBA)
Kittitas County
Kittitas County Sheriff -Jail
CONTRACTOR ADDRESS
CONTRACTOR CONTRACT MANAGER
205 W 5th Avenue, Suite 1 (Jail)
Name: Clay Myers
Ellensburg, WA 98926
Email: clay, mers co.kittitas.wa.us
AMENDMENT START DATE
AMENDMENT END DATE
CONTRACT END DATE
July 1, 2024
June 30, 2025
June 30, 2025
Prior Maximum Contract Amount
Amount of Increase
Total Maximum Compensation
$752,775
$265,000
$1,017,775
WHEREAS, HCA and Contractor previously entered into a Contract for Medication for Opioid Use Disorder
(MOUD) in Jails services, and;
WHEREAS, HCA and Contractor wish to amend the Contract pursuant to Section 4.3, Amendments, to amend
the Nondiscrimination section, and to add funding and deliverables for SFY2025;
NOW THEREFORE, the parties agree the Contract is amended as follows:
1. Special Terms and Conditions, section 3.2, Term, subsection 3.2.1 is amended to extend the Contract
End Date to June 30, 2025.
2. Special Terms and Conditions, section 3.3, Compensation, subsection 3.3.1 is amended to increase
Contract Total Maximum Compensation by $265,000 from $752,775 to $1,017,775.
3. General Terms and Conditions, section 4.25, Nondiscrimination is amended in its entirety with the
following:
4.25. Nondiscrimination
4.25A Nondiscrimination Requirement. During the term of this Contract, Contractor, including any
subcontractor, shall not discriminate on the bases enumerated at RCW 49.60.530(3); Title
VII of the Civil Rights Act, 42 U.S.C. §12101 et seq.; the Americans with Disabilities Act of
1990 (ADA), 42 U.S.C. §12101 et seq., and 28 C.F.R. Part 35. In addition, Contractor,
including any subcontractor, shall give written notice of this nondiscrimination requirement
to any labor organizations with which Contractor, or subcontractor, has a collective
bargaining or other agreement.
4.25.2 Obligation to Cooperate. Contractor, including any subcontractor, shall cooperate and
comply with any Washington state agency investigation regarding any allegation that
Contractor, including any subcontractor, has engaged in discrimination prohibited by this
Contract pursuant to RCW 49.60.530(3).
Washington State Page 1 of 10 MOUD in Jails Services
Health Care Authority HCA Contract No. K5885-3
DoouSign Envelope ID: 666BF09F-322B-4B80-BCBO-40579A7ED52C
4.25.3 Default. Notwithstanding any provision to the contrary, HCA may suspend Contractor,
including any subcontractor, upon notice of a failure to participate and cooperate with any
state agency investigation into alleged discrimination prohibited by this Contract, pursuant
to RCW 49.60.530(3). Any such suspension will remain in place until HCA receives
notification that Contractor, including any subcontractor, is cooperating with the
investigating state agency. In the event Contractor, or subcontractor, is determined to
have engaged in discrimination identified at RCW 49.60.530(3), HCA may terminate this
Contract in whole or in part, and Contractor, subcontractor, or both, may be referred for
debarment as provided in RCW 39.26.200. Contractor or subcontractor may be given a
reasonable time in which to cure this noncompliance, including implementing conditions
consistent with any court -ordered injunctive relief or settlement agreement.
4.25.4 Remedies for Breach. Notwithstanding any provision to the contrary, in the event of
Contract termination or suspension for engaging in discrimination, Contractor,
subcontractor, or both, shall be liable for contract damages as authorized by law including,
but not limited to, any cost difference between the original contract and the replacement or
cover contract and all administrative costs directly related to the replacement contract,
which damages are distinct from any penalties imposed under Chapter 49.60, RCW. HCA
shall have the right to deduct from any monies due to Contractor or subcontractor, or that
thereafter become due, an amount for damages Contractor or subcontractor will owe HCA
for default under this provision.
4. Schedule A-3, Statement of Work, is added hereto and incorporated herein.
5. This Amendment will be effective July 1, 2024 ("Effective Date").
6. All capitalized terms not otherwise defined herein have the meaning ascribed to them in the Contract.
7. All other terms and conditions of the Contract remain unchanged and in full force and effect.
The parties signing below warrant that they have read and understand this Amendment and have authority to
execute the Amendment. This Amendment will be binding on HCA only upon signature by both parties.
CONTRACTOR SIGNATURE
PRINTED NAME AND TITLE
DATE SIGNED
a�ay vJ
469Y i»YAt- S, S rf-,eI ,F
4'-;Z 6 -,y y
HCA SIGNA URE
APd8TWRI®VeffATITLE
DATE SIGNED
oocmftned by:
5/14/2024
A -A. L . o .cc
Deputy Contracts Administrator
`--F2EF77E93FBC4D7
Washington State Page 2 of 10 MOUD in Jails Services
Health Care Authority HCA Contract No. K5885-3
DocuSfgn Envelope ID: 666BF09F-322B-4B80-BCBO-40579A7ED52C
Schedule A-3
STATEMENT OF WORK
1. Purpose
Support a comprehensive treatment program for incarcerated individuals with Opioid Use Disorder (OUD)
and Alcohol Use Disorder (AUD), beginning with screening upon entry and ending with seamless transition to
the care in the community, with use of Medications for Opioid Use Disorder (MOUD) and Medications for
Alcohol Use Disorder (MAUD) at its core.
This program contract supports RCW 71.24.599: Opioid use disorder -City and county 'ails--Fundinq.
wa. ov .
Health Equity - This program also intends to address inequities in treatment and recovery services by
providing medically necessary treatment to incarcerated individuals. Programs should understand cultural
barriers and provide culturally appropriate services. Additionally, this program intends to identify stigma and
educate to ensure ongoing collaboration and openness to change.
2. Acronyms and Definitions
2.1. AI/AN means American Indian/Alaska Native.
2.2. AUD means Alcohol Use Disorder.
2.3. Contractor and Jail may be used interchangeably within this Statement of Work. The Contractor is
responsible for ensuring the Statement of Work is performed within the jail.
2.4. IHCP means Indian Health Care Provider.
2.5. MAUD means Medications for Alcohol Use Disorder.
2.6. MCO means Managed Care Organizations.
2.7. MOUD means Medications for Opioid Use Disorder.
2.8. OTP means Opioid Treatment Program.
2.9. OUD means Opioid Use Disorder.
3. Work Expectations
The Contractor shall ensure funds are responsibly used towards the OUD and AUD treatment programs in
the jail and provide the community standard of care, including, at a minimum, the following core components:
3.1. General Standards.
11.1. 2020 ASAM National Practice Guideline for the Treatment of O ioid Use Disorder,
3.1.2. Guidelines for Manacling Substance Withdrawal in Jails;
Washington State Page 3 of 10 MOUD in Jails Services
Health Care Authority HCA Contract No, K5885-3
Schedule A-3
DocuSign Envelope ID: 666BF09F-322B-4BBO-BCBO-40579A7ED52C
3.1.3 For AI/AN program participants receiving MOUD/MAUD Services, the Contractor's Tribal
Liaison or designee, shall coordinate with the program participant's Indian Health Care
Provider (IHCP) to ensure the IHCP can participate in treatment and discharge planning,
including continuity of care in the nearest IHCP clinically appropriate setting for all AI/AN
program participants.
3.2. Intake.
3.2.1. Continue MOUD and MAUD for individuals who are already taking these medications upon
entering the facility.
3.2.2. Continue the individual on the same medication at the same dose unless ordered otherwise
by the prescriber based on clinical need (documented in the individual's medical record) with
the exceptions listed below:
3.2.2.1. Injectable long -acting naltrexone may be converted to an equivalent oral dose until
just prior to release at which time the injectable form shall be restarted.
3.2.2.2. Injectable long -acting buprenorphine may be converted to an equivalent oral dose
until just prior to release at which time the injectable form shall be restarted.
3.2.2.3. Oral buprenorphine may be converted among the three formulations (film, tablet
with naloxone, tablet without naloxone).
3.2.2.4. If the individual is not pregnant, methadone may be transitioned to buprenorphine if
the jail is not a licensed Opioid Treatment Program (OTP) and the nearest OTP is
not within reasonable driving distance from the jail or there is no OTP within
reasonable distance of the individual's release residence.
3.2.2.5. Though MOUD/MAUD may not be discontinued on a policy or administrative basis
because of the presence of other illicit or controlled substances, administration of
the community -based MOUD or MAUD may be adjusted if clinically necessary due
to pharmacologic risks of drug -drug interaction.
3.2.3. Screen all newly admitted individuals for risk of acute withdrawal from opioids and alcohol
upon intake.
3.2.4. Screen for OUD and AUD without physical dependence (i.e. without a risk of acute
withdrawal) after intake, as long as the delay does not impair the ability to begin treatment
prior to release.
3.2.5. Offer initiation of MOUD treatment to individuals who are physically dependent on opioids.
3.2.6. Educate individuals on treatment choices and the process for continuation of access to
MOUD, during incarceration, and upon release.
3.2.7. Make available and offer treatment using some formulation of methadone, buprenorphine, and
naltrexone based on a mutually agreed -upon plan between the prescriber and the individual,
with the following exceptions or caveats:
3.2.7.1. The jail may decline to offer methadone if the jail is not a licensed OTP and the
nearest OTP is not within reasonable driving distance from the jail or there is no
OTP within reasonable distance of the individual's release residence.
Washington State Page 4 of 10 MOUD in Jails Services
Health Care Authority HCA Contract No. K5885-3
Schedule A-3
DocuSign Envelope ID: 666BF09F-322B-4BB9-BGBO-40579A7ED52G
3.2.7.2. If there is no available buprenorphine provider in the community to which the
individual will release, the Jail must still offer buprenorphine (tapered over several
days) if opioid withdrawal is clinically indicated.
3.2.7.3. If withdrawal is not clinically indicated and the only reason for considering
discontinuation of buprenorphine is the lack of an available buprenorphine provider
in the community to which the individual will release, a decision whether or not — or
when — to discontinue buprenorphine prior to release should be made based on a
plan mutually agreed -upon between the individual and the prescriber based on the
length of time the individual is expected to remain in the jail, the risks of opioid
misuse or overdose during the incarceration, and the individual's willingness to
receive a dose of an extended release injectable buprenorphine just prior to release
that will provide the individual a safe tapered withdrawal in the community if no
provider is available.
3.2.7.4. Provide naltrexone in oral formulation while the individual is incarcerated. Offer
injectable long -acting naltrexone or buprenorphine as an option prior to release.
3.2.7.5. Offer oral buprenorphine without naloxone while the individual is incarcerated but
must discharge the individual on a formulation of buprenorphine with naloxone
unless there is a clinical reason not to do so (e.g., the individual is discharged on
injectable buprenorphine, the individual is allergic to naloxone).
3.2.8. Contractor shall not facilitate forced opioid withdrawal (including withdrawal using a tapering
dose of buprenorphine or methadone) unless the individual provides an informed refusal of
treatment or the individual elects MOUD treatment with naltrexone, in which case withdrawal
is clinically required.
3.2.8.1. In such case, Contractor may use other medications (clonidine, anti -emetics, anti-
diarrheals, analgesics) in place of buprenorphine or methadone if the individual so
chooses or as adjuncts to these medications, but they may not be the only
withdrawal treatment available.
3.2.8.2. Initiation of buprenorphine or methadone, whether for induction of treatment or for
withdrawal, may not be delayed for administrative reasons, e.g., unavailability of a
prescriber, beyond when they are clinically indicated to be started.
3.2.9. Offer treatment for withdrawal with benzodiazepines to individuals entering the facility who are
physically dependent on alcohol, if clinically appropriate.
3.2.10. Provide immediate evaluation to individuals at risk for, or in, opioid or alcohol withdrawal who
refuse treatment by a medical or mental health prescriber or a licensed mental health
professional at the masters' level or higher, to determine if they have decision -making
capacity. If they do not, they must be transported to a community hospital and may not return
to the jail until they are clinically safe to return to the jails AND have regained decision -making
capacity.
Washington State Page 5 of 10 MOUD in Jails Services
Health Care Authority FICA Contract No. K5885-3
Schedule A-3
DocuSign Envelope ID: 666BF09F-322B-4BB0-BCBD-40579A7ED52C
3.3 During Incarceration.
3.3.1 Offer initiation of MOUD/MAUD to individuals with OUD/AUD not already identified and/or
offered treatment at intake (e.g., individuals with OUD but without physical dependence;
individuals with AUD who underwent withdrawal).
3.3.2 Educate individuals on treatment choices and the process for continuation of access to
MOUD/MAUD, during incarceration, and upon release.
3.3.3 Administer methadone and buprenorphine daily or more frequently.
3.3.4 Contractor will not use alternate -day ("Balloon") dosing of buprenorphine.
3.3.5 Offer counseling to individuals for their OUD and/or AUD disorder who are expected to remain
in jail for longer than one month.
3.3.6 Provide MOUD/MAUD not contingent on the individual's willingness to participate in
counseling.
3.4 Release. The Jail must accomplish the following prior to release:
3.4.1 Complete release planning and reentry coordination as soon as possible after admission to
ensure an effective plan is in place prior to release or in the event of an unexpected release of
an individual who needs continued treatment and services.
3.4.2 Provide at least two (2) doses of naloxone (e.g., Narcan®) or nalmefene (Opvee(D) and
training on how to administer the medications to all individuals with OUD.
3.4.3 Schedule the first community appointment with a treatment facility for continuation of MOUD
or MAUD.
3.4.4 Provide - in hand, upon release, and at no cost to the individual - sufficient doses of MOUD
and/or MAUD to bridge individual until scheduled MOUD/MAUD follow-up appointment at
community treatment facility (does not apply to individuals treated with injectable
MOUD/MAUD).
3.4.4.1 Inform individuals who are at risk of being released directly from court, prior to going
to court, that they may request to be transported back to the jail by staff to receive
these medications prior to going home.
3.4.4.2 In situations where an appointment cannot be made, e.g., after-hours bail -out, give
the individual enough medication to last until the next available appointment at the
community treatment facility. If the appointment date is unknown, give individual a
minimum of a 30-day supply.
3.4.4.3
In situations where medications cannot be provided upon release, e.g.,
unscheduled release at a time when medical staff are not present in the jail:
3.4.4.3.1 Inform the individual that they may either return to the jail in the
morning to receive bridge medications; or
3.4.4.3.2 If no medical staff are present the following day, call in a prescription
for the same bridging medication to a local pharmacy, at no cost to the
individual.
Washington State Page 6 of 10 MOUD in Jails Services
Health Care Authority HCA Contract No. K5885-3
Schedule A-3
DocuSign Envelope ID: 666BF09F-322B-4B80-BCBO-40579A7ED52C
3.4.5 Assist Medicaid -eligible individuals to sign-up with Medicaid or assist individuals whose
Medicaid coverage has been terminated to reestablish coverage.
3.4.6 For any individual with Medicaid coverage, work cooperatively with the individual's
Managed Care Organizations (MCO) to facilitate re-entry, including but not limited to
allowing the MCO's agent timely access to the facility and the individual.
3.5 Contract Management.
3.5.1 Ensure specific tools, such as job descriptions, policies and procedures, and statements of
work, are developed, and staff are adequately trained, to ensure consistent and appropriate
practice.
3.5.2 Attend monthly meetings with HCA DBHR program administrator to discuss project contract
requirements, compliance, and problem -solving. Attend additional meetings as required or
deemed necessary by the HCA DBHR program administrator.
3.5.3 Contractor will cooperate with periodic site visits by the HCA DBHR program administrator or
designee and make all relevant records and personnel available.
4. Reports
4.1 Monthly Progress Reports. Reports shall include, but not limited to, the following:
4.1.1 How funding is being spent.
4.1.1.1 Prioritize funding towards efforts to sustain the MOUD/MAUD program.
4.1.1.2 Budget updates.
4.1.2 Program details.
4.1.2.1 All components of the standard of care must be met.
4.1.2.2 Share barriers and successes.
4.1.2.3 Technical assistance.
4.1.2.4 Training participation.
4.1.2.5 Staff changes.
4.1.2.6 Additional information as needed.
4.1.3 Ongoing Staff Training
4.1.3.1
4.1.3.2
Name(s) and date(s) of conference(s) or training event(s) that pertain to MOUD or
MAUD in a jail setting or otherwise deemed appropriate.
Program staff attendance for each conference or training event.
Washington State Page 7 of 10 MOUD in Jails Services
Health Care Authority HCA Contract No. K5885-3
Schedule A-3
DocuSign Envelope ID: 666BF09F-322B-4B60-BCBO-40579A7ED52C
4.2 Monthly Data Collection Spreadsheet.
4.2.1 Data spreadsheet filled out completely with Section 4.2.3 below, following template
provided by HCA and shared via the Managed File Transfer (MFT) portal.
4.2.2 Participation requires performance monitoring activities, including timely and accurate
data reporting to the Health Care Authority, Division of Behavioral Health and Recovery
(HCA DBHR). Further evaluation, including on- and off -site data collection may be
conducted by HCA DBHR or a third party.
4.2.3 The contractor will submit a monthly report, template provided by HCA DBHR, by the
10th day of the month with the following participant information, (identified as having a
current OUD), for the previous month:
4.2.3.1 Full name.
4.2.3.2 Date of birth.
4.2.3.3 Provider One #, SSN or another unique identifier.
4.2.3.4 Date of booking.
4.2.3.5 Date MOUD started: continued or induction?
4.2.3.6 Date of release if applicable.
4.2.3.7 Schedule first appointment upon release.
4.2.3.8 Which MOUD provided upon release.
4.2.4 Information will be collected via the Managed File Transfer (MFT). It may be shared with
Research Data and Analysis (RDA) for evaluation purposes.
5. Allowable expenses. The following is a list of allowable expenses. Contractor shall submit items not on this
list to HCA Contract Manager for approval before purchasing.
5.1 Program Staff.
5.1.1
5.1.2
5.1.3
5.1.4
5.1.5
5.1.6
Nursing.
Medical assistants.
Providers, prescribers.
Correctional staff.
Clerical or administrative staff for program reporting and administration.
Care navigators, reentry coordinators, peer support, substance use disorder professionals,
community health workers.
Washington State Page 8 of 10 MOUD in Jails Services
Health Care Authority HCA Contract No. K5885-3
Schedule A-3
DocuSign Envelope ID: 666BF09F-322B-4680-BCBD-40579A7ED52C
5.2 MOUD/Medications.
5.2.1 Medications for opioid use disorder (MOUD) FDA approved buprenorphine, (this can include
long -acting injectable buprenorphine), methadone and naltrexone.
5.2.2 FDA approved medications for alcohol use disorder (MAUD).
5.2.3 Naloxone for jail and staff.
5.3 Program Supplies.
5.3.1 Technology:
5.3.1.1 Tablets.
5.3.1.2 Phones.
5.3.1.3 Security.
5.3.1.4 Internet/wi-fi enhancements to allow for telehealth.
5.3.1.5 Other supplies approved by HCA Contract Manager prior to purchase.
5.3.2 Program Staff Office Needs:
5.3.2.1 Desk.
5.3.2.2 Chair,
5.3.2.3 Computer.
5.3.2.4 Phone.
5.4 Release and Reentry.
5.4.1 Transportation for program participants upon release to first appointment, pick up
prescription, safe place, etc.
5.4.2 Release kit items such as:
5.4.2.1 Naloxone.
5.4.2.2 Gift cards.
5.4.2.3
Clothing, shoes.
5.4.2.4
Personal hygiene items.
5.4.2.5
Phones.
Washington State Page 9 of 10 MOUD in Jails Services
Health Care Authority HCA Contract No. K5885-3
Schedule A-3
DocuSign Envelope ID: 566BF09F-322B-4B80-BCBO-40579A7ED52C
6. Deliverables Table
#
Description
Due Date
Rate
Amount
1
Monthly Progress
July 2024-May 2025: the 10th
$11,000 per report
$132,500
Report
day of the month following each
x 11 reports
month of service
.. ..................................................................................................................................................
June 2025: With final invoice
............
$11,500 per report
x 1 report
2
Monthly Data
July 2024-May 2025: the 10th
$11,000 per report
$132,500
Collection
day of the month following each
x 11 reports
Spreadsheet
month of service
.........................................................................................................................................................................
June 2025: With final invoice
$11,500 per report
x 1 report
Total Maximum Compensation for deliverables completed
$265,000
through June 30, 2025
Washington State Page 10 of 10 MOUD in Jails Services
Health Care Authority FICA Contract No. K5885-3
Schedule A-3